Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2016', provides an overview of the Heterozygous familial hypercholesterolemia (heFH) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH)
- The report reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Heterozygous familial hypercholesterolemia (heFH) therapeutics and enlists all their major and minor projects
- The report assesses Heterozygous familial hypercholesterolemia (heFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH)


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heterozygous familial hypercholesterolemia (heFH) Overview 6
Therapeutics Development 7
Pipeline Products for Heterozygous familial hypercholesterolemia (heFH) - Overview 7
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics under Development by Companies 8
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Heterozygous familial hypercholesterolemia (heFH) - Products under Development by Companies 12
Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development 13
Kastle Therapeutics LLC 13
Merck & Co., Inc. 14
Pfizer Inc. 15
Regeneron Pharmaceuticals, Inc. 16
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
(atorvastatin calcium + ezetimibe) - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
alirocumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
anacetrapib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
bococizumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MGL-3196 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MGL-3745 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
mipomersen sodium - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Heterozygous familial hypercholesterolemia (heFH) - Recent Pipeline Updates 42
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects 57
Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones 58
Featured News & Press Releases 58
May 24, 2016: New Cholesterol Treatment Now Available for Canadians 58
Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy 59
Mar 16, 2016: Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection and Will Appeal 59
Feb 08, 2016: NICE issues draft guidance on alirocumab for lipid disorder 60
Dec 11, 2015: Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent (alirocumab) Injection for Preferred Access 61
Nov 10, 2015: Regeneron and Sanofi Announce New Praluent Injection Analyses Presented at AHA Scientific Sessions 2015 62
Jul 24, 2015: Sanofi And Regeneron Announce FDA Approval Of Praluent (Alirocumab) Injection, The First Pcsk9 Inhibitor In The U.S., For The Treatment Of High LDL Cholesterol In Adult Patients 63
Mar 27, 2014: Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session 65
Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Kastle Therapeutics LLC, H1 2016 13
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Merck & Co., Inc., H1 2016 14
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Pfizer Inc., H1 2016 15
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Assessment by Combination Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Heterozygous familial hypercholesterolemia (heFH) Therapeutics - Recent Pipeline Updates, H1 2016 42
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H1 2016 57